Goserelin 10.8 mg

DRUG3 trials

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, German Oncology Center, Cyprus, Radboud University Medical Center

Conditions

Prostate AdenocarcinomaProstate CancerRadiation ToxicitySalivary Duct Carcinoma

Phase 1

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

Active, not recruitingNCT05003752

German Oncology Center, CyprusProstate Adenocarcinoma, Radiation Toxicity

Start: 2021-08-01End: 2026-08-01Updated: 2023-03-07

Phase 2

Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolProstate Cancer

Start: 2019-04-01End: 2023-12-01Target: 75Updated: 2022-12-16

Phase II Dutasteride in Combination With CAB vs CAB in SDC

RecruitingNCT05513365

Radboud University Medical CenterSalivary Duct Carcinoma

Start: 2022-09-27End: 2027-09-30Target: 26Updated: 2025-06-04

Related Papers

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.

2024-09-204 citations

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials

Frontiers in Pharmacology2023-06-2610 citations

A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery

Frontiers in Oncology2023-01-13